These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27297028)

  • 1. Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models.
    Taguchi R; Shikata K; Furuya Y; Ino M; Shin K; Shibata H
    Behav Brain Res; 2016 Oct; 312():138-47. PubMed ID: 27297028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective corticotropin-releasing factor 1 receptor antagonist E2508 reduces restraint stress-induced defecation and visceral pain in rat models.
    Taguchi R; Shikata K; Furuya Y; Hirakawa T; Ino M; Shin K; Shibata H
    Psychoneuroendocrinology; 2017 Jan; 75():110-115. PubMed ID: 27810704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.
    Chaki S; Nakazato A; Kennis L; Nakamura M; Mackie C; Sugiura M; Vinken P; Ashton D; Langlois X; Steckler T
    Eur J Pharmacol; 2004 Feb; 485(1-3):145-58. PubMed ID: 14757135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.
    Takahashi Y; Hibi S; Hoshino Y; Kikuchi K; Shin K; Murata-Tai K; Fujisawa M; Ino M; Shibata H; Yonaga M
    J Med Chem; 2012 Jun; 55(11):5255-69. PubMed ID: 22587443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
    Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
    Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
    Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
    J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the CRF
    Wróbel A; Serefko A; Szopa A; Rojek K; Poleszak E; Skalicka-Woźniak K; Dudka J
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Aug; 390(8):769-774. PubMed ID: 28429110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
    Wesołowska A; Nikiforuk A
    Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
    Griebel G; Simiand J; Steinberg R; Jung M; Gully D; Roger P; Geslin M; Scatton B; Maffrand JP; Soubrié P
    J Pharmacol Exp Ther; 2002 Apr; 301(1):333-45. PubMed ID: 11907191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.
    Louis C; Cohen C; Depoortère R; Griebel G
    Neuropsychopharmacology; 2006 Oct; 31(10):2180-7. PubMed ID: 16452986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone.
    Griebel G; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1998 Jul; 138(1):55-66. PubMed ID: 9694527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression.
    Overstreet DH; Griebel G
    Eur J Pharmacol; 2004 Aug; 497(1):49-53. PubMed ID: 15321734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice.
    Bhutada P; Mundhada Y; Bansod K; Ubgade A; Quazi M; Umathe S; Mundhada D
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):955-60. PubMed ID: 20447436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice.
    Birkett MA; Shinday NM; Kessler EJ; Meyer JS; Ritchie S; Rowlett JK
    Pharmacol Biochem Behav; 2011 Jun; 98(4):544-51. PubMed ID: 21397628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.
    Gutman DA; Owens MJ; Skelton KH; Thrivikraman KV; Nemeroff CB
    J Pharmacol Exp Ther; 2003 Feb; 304(2):874-80. PubMed ID: 12538845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist.
    Heinrichs SC; De Souza EB; Schulteis G; Lapsansky JL; Grigoriadis DE
    Neuropsychopharmacology; 2002 Aug; 27(2):194-202. PubMed ID: 12093593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups.
    Kehne JH; Coverdale S; McCloskey TC; Hoffman DC; Cassella JV
    Neuropharmacology; 2000 Jun; 39(8):1357-67. PubMed ID: 10818252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats.
    Carr GV; Schechter LE; Lucki I
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):499-507. PubMed ID: 20217056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.